Intravenous bisphosphonate therapy for osteoporosis: where do we stand?
HG Bone, W Schurr - Current Osteoporosis Reports, 2004 - Springer
HG Bone, W Schurr
Current Osteoporosis Reports, 2004•SpringerThe use of oral bisphosphonates, particularly members of the aminobisphosphonate
subclass, is well established for the treatment of osteoporosis. In a number of clinical
settings, intravenous administration appears to be advantageous. However, current dosing
and efficacy data are limited while definitive, long-term trials with some of these agents are
ongoing. In this article, we review the available information and discuss the use of these
drugs on that basis.
subclass, is well established for the treatment of osteoporosis. In a number of clinical
settings, intravenous administration appears to be advantageous. However, current dosing
and efficacy data are limited while definitive, long-term trials with some of these agents are
ongoing. In this article, we review the available information and discuss the use of these
drugs on that basis.
Abstract
The use of oral bisphosphonates, particularly members of the aminobisphosphonate subclass, is well established for the treatment of osteoporosis. In a number of clinical settings, intravenous administration appears to be advantageous. However, current dosing and efficacy data are limited while definitive, long-term trials with some of these agents are ongoing. In this article, we review the available information and discuss the use of these drugs on that basis.
Springer